- Home
- DMO vs GNLX Comparison
DMO vs GNLX Comparison
Compare DMO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMO
- GNLX
- Stock Information
- Founded
- DMO 2009
- GNLX 2001
- Country
- DMO United States
- GNLX United States
- Employees
- DMO N/A
- GNLX N/A
- Industry
- DMO Trusts Except Educational Religious and Charitable
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- DMO Finance
- GNLX Health Care
- Exchange
- DMO Nasdaq
- GNLX Nasdaq
- Market Cap
- DMO 136.8M
- GNLX 128.0M
- IPO Year
- DMO N/A
- GNLX 2023
- Fundamental
- Price
- DMO $11.93
- GNLX $7.30
- Analyst Decision
- DMO
- GNLX Strong Buy
- Analyst Count
- DMO 0
- GNLX 5
- Target Price
- DMO N/A
- GNLX $17.40
- AVG Volume (30 Days)
- DMO 49.6K
- GNLX 207.8K
- Earning Date
- DMO 01-01-0001
- GNLX 11-13-2025
- Dividend Yield
- DMO 12.06%
- GNLX N/A
- EPS Growth
- DMO N/A
- GNLX N/A
- EPS
- DMO N/A
- GNLX N/A
- Revenue
- DMO N/A
- GNLX N/A
- Revenue This Year
- DMO N/A
- GNLX N/A
- Revenue Next Year
- DMO N/A
- GNLX N/A
- P/E Ratio
- DMO N/A
- GNLX N/A
- Revenue Growth
- DMO N/A
- GNLX N/A
- 52 Week Low
- DMO $10.00
- GNLX $1.99
- 52 Week High
- DMO $11.80
- GNLX $8.27
- Technical
- Relative Strength Index (RSI)
- DMO 52.39
- GNLX 78.62
- Support Level
- DMO $11.82
- GNLX $6.16
- Resistance Level
- DMO $12.08
- GNLX $8.26
- Average True Range (ATR)
- DMO 0.11
- GNLX 0.61
- MACD
- DMO 0.00
- GNLX 0.23
- Stochastic Oscillator
- DMO 47.49
- GNLX 85.09
About DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.